We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Jul 2021
  • Code : CMI1357
  • Industry : Pharmaceutical
  • Pages : 188
  • Formats :

Diabetic foot ulcers are common complication of poorly controlled diabetes, forming as a result of skin tissue breaking down and exposing the layers underneath. It is commonly located on the bottom of the foot. The major causes of diabetic ulcers includes , high blood sugar, nerve damage, and irritated or wounded feet.

The global diabetic foot ulcer treatment market is estimated to be valued at US$ 6,411.3 million in 2021 and is expected to exhibit a CAGR of 10.2% during the forecast period (2021-2028).

Figure 1.Global Diabetic Foot Ulcer Treatment Market Share (%) in Terms of Value, By Product, 2021

Diabetic Foot Ulcers Treatment  | Coherent Market Insights

Increasing prevalence of diabetes and subsequent rise in incidence of diabetic foot ulcers is expected to drive the market growth during the forecast period.

Increasing prevalence of diabetes and subsequent rise in incidence of diabetic foot ulcers is expected to drive the global diabetic foot ulcer treatment market growth over the forecast period. For instance, according to the American Diabetes Association, in 2018, 34.2 million Americans, or 10.5% of the population, had diabetes. Moreover, according to the Diabetic Foot Journal, in 2019, around 169,000 individuals had diabetic foot ulcers in the U.K.

CMI table icon

Diabetic Foot Ulcer Treatment Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 6,411.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 10.2% 2028 Value Projection: US$ 12,653.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product: Advance Wound Dressings, Skin Substitutes, Growth Factors, Negative Pressure Wound Therapy Devices, Other Devices
  • By Ulcer Type: Neuropathic Ulcers, Ischemic Ulcers, Neuro-Ischemic Ulcers
  • By End User: Hospitals, Specialty Clinics, Long Term Care Centers, Ambulatory Surgical Centers
Companies covered:

3M Healthcare, B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, and Molnlycke Health Care AB

Growth Drivers:
  • Increasing prevalence of diabetes and subsequent rise in incidence of diabetic foot ulcers
  • Availability of explicit dressings for specific type of foot ulcers
Restraints & Challenges:
  • High cost of diabetic foot ulcer medication and care

Figure 2.Global Diabetic Foot Ulcer Treatment Market Share (%), , 2021

Diabetic Foot Ulcers Treatment  | Coherent Market Insights

Availability of explicit dressings for specific type of foot ulcers is expected to drive the market growth during the forecast period.

Availability of explicit dressings for specific type of diabetic  is expected to boost the market growth during the forecast period. For instance, hydrocolloid dressings such as DuoDERM or IntraSite hydrocolloid are available for  . Such dressings help to maintain moist environment for faster wound healing and allow autolytic debridement. Absorptive dressings including calcium alginates (e.g., Kaltostat and Curasorb) are available for exudative wounds in  

Global Diabetic Foot Ulcer Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. For instance, according to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in over 190 million infected individuals worldwide as of July 19, 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global diabetic foot ulcer treatment market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.

Global Diabetic Foot Ulcer Treatment Market: Restraint

The major factors that are expected to hinder growth of the global diabetic foot ulcer treatment market include high cost of diabetic foot ulcer medication and care. For instance, according to the Therapeutic Advances in Endocrinology and Metabolism 2018, the total medical cost for the management of diabetic foot disease ranges from US$ 9 to US$ 15 billion in the U.S.

Key Players

Major players operating in the global diabetic foot ulcer treatment market include 3M Healthcare, B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, and Molnlycke Health Care AB.

Diabetic foot ulcer is a common condition in diabetic patients, which may lead to amputation of the leg. People who rely on insulin for the treatment of diabetes are at high risk of developing a foot ulcer. Moreover, people suffering from diabetes-related kidney, eye, and heart disease and obesity can also suffer from diabetic foot ulcers. The risk of the disease is high in those consuming alcohol and tobacco. The common initial symptoms of diabetic foot ulcer include unusual swelling, redness, irritation, and stenches on one or both feet. Diabetic foot ulcer treatment, usually include control of blood sugar, removal of dead tissue, wound dressings, and negative pressure therapy.

Market Dynamics

Key players operating in the global diabetic foot ulcer treatment market are focusing on adoption of growth strategies such as product launches and regulatory approvals, which are expected to drive the market growth during the forecast period. For instance, in November 2019, Pergamum AB, a subsidiary of Promore Pharma AB, a Sweden-based biopharmaceutical company, received a patent in the U.S. for the pharmaceutical formulation of the product candidate PXL01 used for the treatment of diabetic foot ulcers. Moreover, in December 2019, Orpyx Medical Technologies Inc., a medical device company that designs and develops sensory insole systems for the treatment of diabetic foot ulcers, launched Orpyx SI Sensory Insoles with for the prevention of diabetic foot ulcers and neuropathy-related ulcers. Furthermore, in December 2017, SANUWAVE Health Inc., received the US approval for marketing of the Dermapace system, the indicated to treat diabetic foot ulcer.

Key features of the study:

  • This report provides in-depth analysis of the global diabetic foot ulcer treatment  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for global diabetic foot ulcer treatment market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global diabetic foot ulcer treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include 3M Healthcare, B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, and Molnlycke Health Care AB
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global diabetic foot ulcer treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic foot ulcer treatment market

Detailed Segmentation:

  • Global Diabetic Foot Ulcer Treatment Market, By Product :
    • Advance Wound Dressings
    • Skin Substitutes
    • Growth Factors
    • Negative Pressure Wound Therapy Devices
    • Other Devices
  • Global Diabetic Foot Ulcer Treatment Market, By Ulcer Type:
    • Neuropathic Ulcers
    • Ischemic Ulcers
    • Neuro-ischemic Ulcers
  • Global Diabetic Foot Ulcer Treatment Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Long Term Care Centers
    • Ambulatory Surgical Center
  • Global Diabetic Foot Ulcer Treatment Market, By Region:
    • North America
      • By Product
        • Advance Wound Dressings
        • Skin Substitutes
        • Growth Factors
        • Negative Pressure Wound Therapy Devices
        • Other Devices
      •  By Ulcer Type
        • Neuropathic Ulcers
        • Ischemic Ulcers
        • Neuro-ischemic Ulcers
      • By End User
        • Hospitals
        • Specialty Clinics
        • Long Term Care Centers
        • Ambulatory Surgical Center
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Product
        • Advance Wound Dressings
        • Skin Substitutes
        • Growth Factors
        • Negative Pressure Wound Therapy Devices
        • Other Devices
      •  By Ulcer Type
        • Neuropathic Ulcers
        • Ischemic Ulcers
        • Neuro-ischemic Ulcers
      • By End User
        • Hospitals
        • Specialty Clinics
        • Long Term Care Centers
        • Ambulatory Surgical Center
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product
        • Advance Wound Dressings
        • Skin Substitutes
        • Growth Factors
        • Negative Pressure Wound Therapy Devices
        • Other Devices
      •  By Ulcer Type
        • Neuropathic Ulcers
        • Ischemic Ulcers
        • Neuro-ischemic Ulcers
      • By End User
        • Hospitals
        • Specialty Clinics
        • Long Term Care Centers
        • Ambulatory Surgical Center
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product
        • Advance Wound Dressings
        • Skin Substitutes
        • Growth Factors
        • Negative Pressure Wound Therapy Devices
        • Other Devices
      •  By Ulcer Type
        • Neuropathic Ulcers
        • Ischemic Ulcers
        • Neuro-ischemic Ulcers
      • By End User
        • Hospitals
        • Specialty Clinics
        • Long Term Care Centers
        • Ambulatory Surgical Center
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product
        • Advance Wound Dressings
        • Skin Substitutes
        • Growth Factors
        • Negative Pressure Wound Therapy Devices
        • Other Devices
      •  By Ulcer Type
        • Neuropathic Ulcers
        • Ischemic Ulcers
        • Neuro-ischemic Ulcers
      • By End User
        • Hospitals
        • Specialty Clinics
        • Long Term Care Centers
        • Ambulatory Surgical Center
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product
        • Advance Wound Dressings
        • Skin Substitutes
        • Growth Factors
        • Negative Pressure Wound Therapy Devices
        • Other Devices
      •  By Ulcer Type
        • Neuropathic Ulcers
        • Ischemic Ulcers
        • Neuro-ischemic Ulcers
      • By End User
        • Hospitals
        • Specialty Clinics
        • Long Term Care Centers
        • Ambulatory Surgical Center
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • 3M Healthcare*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Braun Melsungen AG
    • Smith & Nephew, Inc.
    • Organogenesis, Inc.
    • Derma Sciences Inc.
    • Sigvaris Inc.
    • Acelity L.P. Inc.
    • Osiris
    • Molnlycke Health Care AB

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global diabetic foot ulcer therapeutics market is estimated to surpass US$ 12,021.8 Million by 2027 .
Major players operating in the global diabetic foot ulcer therapeutics market include B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., 3M, and Acelity L.P. Inc.
High cost of diabetic foot ulcer medication and careis one of the major factors that is expected to hamper growth of the market over the forecast period.
Increasing prevalence of diabetes and subsequent rise in incidence of diabetic foot ulcersis one of the major factors that is expected to propel growth of the market over the forecast period.
Rising demand for biologic skin substitutes such as Apligraf and DermaGraft (Organogenesis Inc.) for the treatment neuropathic diabetic foot ulcers is one of the major trends that has been observed in the market.
Among regions, North America held dominant position in the global diabetic foot ulcer therapeutics market in 2018 , accounting for 37.8% share , in terms of volume, followed by Europe.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo